- US FDA snubs Janssen's Xarelto for acute coronary syndrome
- Janssen gets 2nd rejection for Xarelto in ACS
- Janssen withdraws one Xarelto sNDA, gets priority review for another
- Bayer wins PE and DVT indications in Europe for Xarelto
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.